Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deferoxamine is a potent iron chelator used primarily to treat acute iron poisoning and chronic iron overload conditions such as those resulting from frequent blood transfusions. It binds free ferric iron (Fe3+) to form a stable complex that can be excreted in urine and bile, thereby reducing tissue iron accumulation. Deferoxamine also has activity as an inhibitor of ferroptosis (iron-dependent cell death) and can modulate hypoxia-inducible factor-1 alpha (HIF-1α) expression, contributing to its antioxidant effects. Off-label, it is sometimes used for aluminum toxicity[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deferoxamine.